Panaxia Labs Israel Ltd
TASE:PNAX
Operating Margin
Panaxia Labs Israel Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
IL |
P
|
Panaxia Labs Israel Ltd
TASE:PNAX
|
7.9m ILS |
-109%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
40%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
26%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
45%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.2B CHF |
33%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
185.9B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
161.7B GBP |
24%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
34%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
136.3B USD |
27%
|
Panaxia Labs Israel Ltd
Glance View
Panaxia Labs Israel Ltd. engages in the manufacture and distribution of medical cannabis products. The firm provides pharma-grade smokeless cannabis products that provide better delivery systems for patients and physicians when properly assessing safety and dosage. Panaxia pharmaceutical cannabis products are specifically tailored to meet a broad range of needs. It's product portfolio includes: NAXIVA-PANAXOL Advanced kit for preparation of cannabis oil-standardized extract, NAXIVA-PANAXOL Purified extract for inhalation, PANAXIR Medical Cannabis Orodispersible Tablets, PANAXIR SENSE Orange Creamsicle Medical cannabis sublingual drops, PANAXIR CBD Melatonin Tablets, PANAXIR Medical cannabis extracts in ethanol among others.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Panaxia Labs Israel Ltd's most recent financial statements, the company has Operating Margin of -109.3%.